Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
| Autor: | K.J. Hillan, Lukas C. Amler, A.D. Goddard |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Lung Neoplasms
Gene Dosage Biochemistry Erlotinib Hydrochloride Gefitinib Epidermal growth factor Carcinoma Non-Small-Cell Lung Genetics medicine Humans Growth factor receptor inhibitor Lung cancer Protein Kinase Inhibitors neoplasms Molecular Biology business.industry Smoking Prognosis medicine.disease Chemotherapy regimen respiratory tract diseases ErbB Receptors Genes ras Mutation Quinazolines Cancer research Immunohistochemistry Erlotinib business Tyrosine kinase Signal Transduction medicine.drug |
| Zdroj: | Cold Spring Harbor Symposia on Quantitative Biology. 70:483-488 |
| ISSN: | 1943-4456 0091-7451 |
| Popis: | Erlotinib and gefitinib are small-molecule inhibitors of the epidermal growth factor tyrosine kinase. Erlotinib is approved for the treatment of locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. Although it is active in unselected patients, clinical characteristics and tumor molecular markers associated with enhanced benefit have been identified. Notably, never-smoker status or a positive EGFR FISH test has been consistently predictive of greater erlotinib benefit. Other markers, such as EGFR mutations and EGFR protein expression, as determined by immunohistochemistry, and KRAS mutation status have not proven to be consistently associated with differential benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|